Welcome to our dedicated page for BiondVax Pharmaceuticals Ltd. news (Ticker: bvxv), a resource for investors and traders seeking the latest updates and insights on BiondVax Pharmaceuticals Ltd. stock.
BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) is a biopharmaceutical company pioneering innovative solutions in the realm of inflammation and immunology (I&I). With a robust pipeline of nanosized VHH antibodies known as NanoAbs, BiondVax is targeting diseases with significant unmet medical needs. The company has made notable strides, particularly with its leading product, an intradermal NanoAb targeting IL-17 for treating mild to moderate plaque psoriasis. This product has shown promising results in preclinical ex-vivo trials and is gearing up for human clinical trials in 2025.
BiondVax operates two main business units. The first focuses on the in-house development of biological therapeutic products, leveraging its NanoAb technology licensed from the Max Planck Society and the University Medical Center Göttingen, Germany. The second unit, Scinai Bioservices, is a boutique Contract Development and Manufacturing Organization (CDMO) that offers end-to-end services ranging from drug development to GMP manufacturing. Launched in Q3 2023, Scinai Bioservices has already secured contracts with several biotechnology companies and aims to support small biotech firms in bringing their products to market efficiently.
The company recently welcomed Liat Halpert as Head of Business Development and Sales. Halpert, with her extensive experience from Novartis, is expected to expand Scinai’s CDMO business, particularly targeting European and U.S.-based biotech companies. This strategic move is anticipated to significantly boost BiondVax's revenue and establish it as a key partner for small biotechnology firms.
In recent news, BiondVax announced successful preclinical results of its IL-17 targeting NanoAb for psoriasis treatment. Additionally, its NanoAbs for COVID-19 have shown efficacy in preclinical trials, demonstrating potential in preventing and treating viral respiratory diseases through inhalation, a convenient administration route.
BiondVax's financial stability and strategic partnerships position it well for future growth. The company continues to seek collaborative opportunities with mid and large-cap pharmaceutical companies to advance its NanoAb therapies through clinical trials and towards commercialization.
For the latest updates and detailed information, visit BiondVax’s official website at www.biondvax.com.
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) announced its participation at the 20th Biomed Israel Conference from May 10-12, 2022, in Tel Aviv, Israel. Dr. Tamar Ben-Yedidia, Chief Scientific Officer, will present on May 12 at 1:45 PM, focusing on the innovative development of nanosized antibodies (NanoAbs) aimed at addressing significant medical needs including asthma and macular degeneration. The NanoAbs are developed in collaboration with the Max Planck Institute and University Medical Center Göttingen in Germany. Investors wishing to connect with management can reach out through investor relations.
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) announced an investor webinar scheduled for April 6, 2022, conducted in Hebrew. CEO Amir Reichman will cover key updates, including the collaboration on the nanosized antibody (NanoAb) pipeline with Max Planck Institute and University Medical Center Göttingen, manufacturing progress in Jerusalem, and negotiations with the European Investment Bank. The webinar will include a Q&A session, time permitting. A prior English-language webinar on NanoAb research is also accessible online.
BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) announced a webinar for analysts and investors on April 4, 2022, at 10 am (ET). CEO Amir Reichman will discuss the development of their nanosized antibody (NanoAb) pipeline, collaboration with Max Planck Institute, and fiscal year 2021 financial results. Professor Matthias Dobbelstein will share insights on NanoAb research. Registration for the webinar is available here.
BiondVax Pharmaceuticals (NASDAQ: BVXV) reported its financial results for Q4 and the full year 2021, highlighting a strategic turnaround and promising developments. Total operating expenses fell to NIS 34.8 million ($11.2 million) in 2021, significantly down from NIS 68.8 million in 2020. The company signed exclusive licensing agreements for COVID-19 NanoAbs and initiated in-house manufacturing, enhancing control over its product pipeline. As of December 31, 2021, cash and cash equivalents increased to NIS 54 million ($17.4 million) due to successful share offerings.
BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) has formed a strategic collaboration with the Max Planck Society and University Medical Center Göttingen to develop innovative nanosized antibodies (NanoAbs). BiondVax has secured exclusive worldwide licensing rights for these therapies, which target diseases with significant market potential, including psoriasis and COVID-19. Initial preclinical results are expected in 2023. The NanoAb platform promises advantages like strong binding affinity and stability, and is supported by BiondVax's advanced manufacturing capabilities in Jerusalem.
BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) announced a preliminary agreement with the European Investment Bank (EIB) to restructure a €24 million loan, extending its maturity until December 2027. The restructuring includes deferred interest payments starting January 1, 2022, and a principal reduction of $900,000. Additionally, once commercial sales exceed €5 million, 3% of revenues will be paid to EIB as royalties. CEO Amir Reichman expressed optimism about the support from EIB, emphasizing its role in advancing BiondVax's innovative antibody pipeline.
BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) announced its participation in the Aegis Capital Corp. Virtual Conference on February 23, 2022, at 9:30am ET. The presentation will highlight the development of innovative nanosized antibodies (NanoAbs) that offer competitive advantages in treating infectious diseases. The presentation will be accessible to Aegis attendees from February 23 to 25 and will also be available on BiondVax's website. The company has conducted eight clinical trials and is focused on developing a diverse pipeline of biopharmaceutical products.
BiondVax Pharmaceuticals (Nasdaq: BVXV) has announced that CEO Amir Reichman will present at the BIO CEO & Investor Conference from February 15, 2022. His presentation highlights a new collaboration aimed at developing innovative therapeutic NanoAbs. Participants can access the presentation on-demand through the conference portal or BiondVax's website. The company is also set to hold virtual meetings with investors during the conference.
BiondVax, established to combat infectious diseases, has conducted several clinical trials and aims to expand its portfolio of therapeutic options.
BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) announced its presentation at the Edison Open House: Global Healthcare 2022 conference on January 26, 2022. The presentation is available on-demand via the conference portal. Management will also hold virtual 1-1 meetings with investors regarding this event. BiondVax focuses on developing innovative biopharmaceutical products for infectious diseases and has conducted multiple clinical trials, including a significant Phase 3 trial with 12,400 participants. For additional details, visit www.biondvax.com.
BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) announced its participation in the H.C. Wainwright Bioconnect Virtual Conference from January 10 to 13, 2022. The company will present an overview, and the presentation will be available on-demand for registered attendees. Additionally, a slide deck will be accessible on BiondVax's website. The company focuses on developing innovative products for infectious diseases, including a nanosized antibody pipeline and has completed eight clinical trials, demonstrating a commitment to diverse and commercially viable therapeutic options.
FAQ
What is the market cap of BiondVax Pharmaceuticals Ltd. (bvxv)?
What does BiondVax Pharmaceuticals Ltd. do?
What are NanoAbs?
What recent achievements has BiondVax made?
Who is Liat Halpert?
What services does Scinai Bioservices offer?
When are human clinical trials for the psoriasis NanoAb expected?
What are the potential applications of BiondVax's NanoAbs?
How is BiondVax planning to expand its CDMO business?
What regulatory approvals does BiondVax need?
Where can I find more information about BiondVax Pharmaceuticals Ltd.?
